News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL July 29, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds EN NL June 30, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL May 31, 2022
General News Regulated Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 EN NL May 25, 2022
General News Regulated Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) EN NL May 9, 2022
General News Regulated Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022 EN NL May 6, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL April 29, 2022
General News Regulated Oxurion Announces Extraordinary and Annual Shareholders’ Meetings EN NL April 1, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA EN NL March 30, 2022
News Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG EN NL March 17, 2022
General News Regulated Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement EN NL March 3, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL February 22, 2022
General News Regulated Oxurion NV announces 2021 Full Year Results and 2022 Outlook EN NL February 22, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL December 30, 2021
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL November 30, 2021
General News Regulated OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures EN November 22, 2021
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices NEGMA EN NL November 3, 2021
General News Regulated OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) EN September 30, 2021
